Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 3/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 3/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | BRAF | P15056 | 1/20 | 0.30 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13723742 | 1.00 | MAP2K2 (0.38) | MAP2K2MAP2K1KCNH2GAAMAPK1 | |
| SCHEMBL5028992 | 0.92 | KCNH2 (0.37) | MAP2K2MAP2K1KCNH2GAAHPGD | |
| SCHEMBL5028995 | 0.90 | MAP2K2 (0.39) | MAP2K2MAP2K1KCNH2GAAMAPK1 | |
| SCHEMBL5031221 | 0.87 | MAP2K1 (0.42) | MAP2K2MAP2K1KCNH2MAPK1BRAF | |
| SCHEMBL5029001 | 0.87 | MAP2K1 (0.39) | MAP2K2MAP2K1GAAHPGDMAP2K5 | |
| SCHEMBL14919911 | 0.82 | MAP2K1 (0.38) | MAP2K2MAP2K1KCNH2GAAMAPK1 | |
| SCHEMBL5031300 | 0.80 | MAP2K1 (0.35) | MAP2K2MAP2K1KCNH2MAPK1 | |
| SCHEMBL5035605 | 0.79 | MAP2K1 (0.40) | MAP2K2MAP2K1KCNH2MAPK1BRAF | |
| SCHEMBL5029045 | 0.77 | MAP2K1 (0.40) | MAP2K2MAP2K1GAAHPGDMAP2K5 | |
| SCHEMBL5028996 | 0.74 | HSD17B10 (0.39) | MAP2K2MAP2K1KCNH2GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2750675-A1 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | Novartis AG (CH) | 2014-07-09 | — | — | EP | disclosed |
| WO-2013066483-A1 | SYNERGISTIC COMBINATIONS OF PI3K- AND MEK-INHIBITORS | NOVARTIS AG (CH) | 2013-05-10 | — | — | WO | disclosed |